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Summary
Background Healthy life expectancy (HALE) and disability-adjusted life-years (DALYs) provide summary measures of 
health across geographies and time that can inform assessments of epidemiological patterns and health system 
performance, help to prioritise investments in research and development, and monitor progress toward the 
Sustainable Development Goals (SDGs). We aimed to provide updated HALE and DALYs for geographies worldwide 
and evaluate how disease burden changes with development. 
Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) 
for all-cause mortality, cause-specifi c mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 
195 countries and territories from 1990 to 2015. We calculated DALYs by summing years of life lost (YLLs) and 
years of life lived with disability (YLDs) for each geography, age group, sex, and year. We estimated HALE using 
the Sullivan method, which draws from age-specifi c death rates and YLDs per capita. We then assessed how 
observed levels of DALYs and HALE diff ered from expected trends calculated with the Socio-demographic Index 
(SDI), a composite indicator constructed from measures of income per capita, average years of schooling, and total 
fertility rate.
Findings Total global DALYs remained largely unchanged from 1990 to 2015, with decreases in communicable, 
neonatal, maternal, and nutritional (Group 1) disease DALYs off set by increased DALYs due to non-communicable 
diseases (NCDs). Much of this epidemiological transition was caused by changes in population growth and ageing, 
but it was accelerated by widespread improvements in SDI that also correlated strongly with the increasing 
importance of NCDs. Both total DALYs and age-standardised DALY rates due to most Group 1 causes signifi cantly 
decreased by 2015, and although total burden climbed for the majority of NCDs, age-standardised DALY rates due 
to NCDs declined. Nonetheless, age-standardised DALY rates due to several high-burden NCDs (including 
osteoarthritis, drug use disorders, depression, diabetes, congenital birth defects, and skin, oral, and sense organ 
diseases) either increased or remained unchanged, leading to increases in their relative ranking in many 
geographies. From 2005 to 2015, HALE at birth increased by an average of 2·9 years (95% uncertainty interval 
2·9–3·0) for men and 3·5 years (3·4–3·7) for women, while HALE at age 65 years improved by 0·85 years 
(0·78–0·92) and 1·2 years (1·1–1·3), respectively. Rising SDI was associated with consistently higher HALE and a 
somewhat smaller proportion of life spent with functional health loss; however, rising SDI was related to increases 
in total disability. Many countries and territories in central America and eastern sub-Saharan Africa had 
increasingly lower rates of disease burden than expected given their SDI. At the same time, a subset of geographies 
recorded a growing gap between observed and expected levels of DALYs, a trend driven mainly by rising burden 
due to war, interpersonal violence, and various NCDs.
Interpretation Health is improving globally, but this means more populations are spending more time with functional 
health loss, an absolute expansion of morbidity. The proportion of life spent in ill health decreases somewhat with 
increasing SDI, a relative compression of morbidity, which supports continued eff orts to elevate personal income, 
improve education, and limit fertility. Our analysis of DALYs and HALE and their relationship to SDI represents a 
robust framework on which to benchmark geography-specifi c health performance and SDG progress. Country-
specifi c drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform fi nancial 
and research investments, prevention eff orts, health policies, and health system improvement initiatives for all 
countries along the development continuum.
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Introduction
Summary measures of population health are crucial inputs 
to guide health system investments and set priorities at 
global, regional, national, and subnational levels. The 
Millennium Development Goals (MDGs), which sought to 
reduce extreme poverty and improve health, expired in 
2015, and were replaced by the 2030 Agenda for Sustainable 
Development, or Sustainable Development Goals (SDGs).1 
The shift from the MDGs to the SDGs refl ects a broadening 
of the global development agenda,2,3 expanding to include 
targets for non-communicable diseases (NCDs) and 
indicators that consider the interplay of environmental, 
societal, and economic factors on health.4 Within this 
context, summary population health measures are 
advantageous because they can easily be used to show 
progress toward SDG 3—to “ensure healthy lives and 
promote well-being for all at all ages”—and provide a 
metric by which comparative progress on other SDGs can 
be monitored.5 Summary measures also provide insights 
into whether, as societies live longer, they spend more or 
less of their time with functional health loss, known as the 
expansion or compression of morbidity, respectively, 
which has profound implications for societies and the 
fi nancing of health systems.
Two types of population health summary measures 
exist: health expectancies and health gaps.6 Healthy life 
expectancy (HALE), which originates from Sullivan,7 
provides a single summary measure of population health 
by weighting years lived with a measure of functional 
health loss experienced before death. Many health 
expectancy measures have been proposed, but HALE is 
the only one that captures a full range of functional 
health loss.8–10 Health gap measures capture diff erences 
between a population and some normative standard such 
as a maximum lifespan in full health. Disability-adjusted 
life-years (DALY) are a widely used gap measure,6,9–11 
representing the sum of years of life lost (YLLs) due to 
premature mortality and years lived with disability 
(YLDs). YLLs quantify the gap between observed 
mortality and a normative life expectancy,12 and YLDs 
capture the prevalence of conditions that lead to non-fatal 
health loss while accounting for the severity of those 
conditions. Health gap measures can be easily 
disaggregated to examine contributions of relative 
morbidity and mortality, individual diseases, injuries, 
and attributable risk factors.
The Global Burden of Diseases, Injuries, and Risk 
Factors (GBD) study is the most comprehensive source of 
comparable summary population health measures 
because of its inclusion of country-level results, 
uncertainty quantifi cation, and its eff ort to maximise 
comparability across geography, time, and across diff erent 
health conditions. Alternative summary health assess-
ments are not as standardised or comprehensive, with 
studies reporting only incomplete time-series, no 
uncertainty measures, or only a subset of countries and 
causes.13–15 WHO published DALY estimates for 2 years 
(2000 and 2012), with 132 causes and 174 countries and 
Research in context
Evidence before this study 
Disability-adjusted life-years (DALYs), a summary measure of 
population health based on estimates of premature mortality 
and non-fatal health loss, originated from the initial Global 
Burden of Disease (GBD) study in 1993. DALYs, in combination 
with other summary measures such as healthy life expectancy 
(HALE), off er relatively simple yet powerful metrics against 
which progress and challenges in improving disease burden and 
extending healthy lifespans can be eff ectively monitored over 
time. Published in 2012, GBD 2010 provided updated estimates 
of DALYs due to 291 causes and HALE in 187 countries from 
1990 to 2010. GBD 2013 extended this time series to 2013, 
with 188 countries, and 306 causes. Novel analyses for 
quantifying epidemiological transitions were introduced as part 
of GBD 2013, enabling a comparison of shifts in years of life lost 
(YLLs) and years lived with disability (YLDs) with increasing 
levels of development. WHO has produced estimates of DALYs 
and HALE largely based on GBD 2010 and GBD 2013; however, 
modifi cations were implemented for a subset of causes, 
disability weights, and countries, and a normative life table of 
91·9 years at birth was used for calculating YLLs. 
Added value of this study 
For GBD 2015, we generated estimates of HALE and DALYs for 
315 causes by geography, sex, and age group from 1990 to 
2015 for 195 countries and territories. We constructed a 
summary metric referred to as the Socio-demographic Index 
(SDI) based on measures of income per capita, average years of 
schooling, and total fertility rate. We estimated SDI for each 
geography-year, and characterised the average relationship for 
each age, sex, and cause for DALYs and HALE with SDI. Using 
these relationships, we calculated expected levels of DALYs, life 
expectancy, and HALE for each geography over time. We 
compared observed patterns of both DALYs and HALE with 
those expected on the basis of SDI, allowing us to explore where 
health gains exceeded—or lagged behind—corresponding 
changes in development.
Implications 
Since 1990, overall health has improved in most countries, with 
particularly large gains occurring in the past 10 years. Although 
improved health means longer lifespans, it also translates to 
more years of functional health lost. The fraction of overall life 
expectancy spent in poor health is generally constant or has 
slightly declined in some countries, a result driven by declines in 
DALYs due to communicable, maternal, nutritional, and neonatal 
causes and increases in others, mainly non-communicable 
diseases. Country-specifi c drivers of disease burden, particularly 
when observed DALYs are higher than expected on the basis of 
SDI, should inform country-specifi c inquiry and action.
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without uncertainty intervals. These estimates were 
derived primarily from GBD 2010 results, but were 
modifi ed in 60 countries and for 12 cause groups 
separately estimated by WHO and UN agencies.13,16,17 
WHO applied the same approach for GBD 2013 results 
and used their own life tables to produce HALE estimates 
for 2015.14 The European Commission (EC) and 
the Organisation for Economic Co-operation and 
Development (OECD) also reported healthy life expectancy 
estimates for European countries from 2004 through 2014, 
but these were based on self-reported health status.18,19
Here we present GBD 2015 fi ndings for DALYs and 
HALE, building upon updated estimates of mortality, 
causes of death, and non-fatal health loss.12,20 Overall 
analytic approaches are similar to previous GBD 
studies,9,10 but include new mortality and morbidity data, 
refi ned methods, and expanded geographies.12,20 This 
report supersedes all previous GBD studies on DALYs 
and HALE through the estimation of a complete time-
series for 1990 to 2015. To facilitate a more in-depth 
examination of the drivers of DALY and HALE trends, we 
assess how HALE, along with overall and cause-specifi c 
DALYs, change as geographies move through the 
development continuum. We use this analysis to 
benchmark overall progress and decompose observed 
disease burden compared with levels expected for specifi c 
causes on the basis of development alone, to highlight 
potential areas for policy investment or further research.
Methods
Overview
Detailed methods for estimating DALYs and HALE, 
including analytic approaches for mortality and non-fatal 
health loss estimation, are provided in related pub-
lications.12,20 Additional detail on GBD metrics and 
defi nitions are found elsewhere.21 Interactive tools are also 
available to explore GBD 2015 results and data sources. 
This analysis follows the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER), which 
includes recommendations on documentation of data 
sources, estimation methods, and statistical analysis.22,23
In brief, the GBD geographic hierarchy involves 519 total 
geographies within 195 countries and territories, 21 regions, 
and seven super-regions. This study reports results for all 
countries and territories. The GBD cause hierarchy has 
four levels of classifi cation and causes reported within each 
level that are mutually exclusive and collectively exhaustive. 
The full GBD cause list with corresponding International 
Classifi cation of Diseases (ICD)-9 and ICD-10 codes are 
available in our publications on cause-specifi c mortality12 
and non-fatal health outcomes.20
Estimation of mortality and non-fatal health loss
We estimated all-cause and cause-specifi c mortality with 
a multistep computation process, which included 
systematically addressing known data challenges, such as 
diff erent coding schemes, diff erent age-group reporting, 
variation in certifi cation, misclassifi cation of HIV/AIDS 
deaths in some countries, misclassifi cation of maternal 
HIV/AIDS deaths, and incorporation of population-based 
cancer registry data, before computation of cause-specifi c 
mortality with analytic tools such as Cause of Death 
Ensemble Modelling (CODEm). Each death could have 
only one underlying cause. Additional detail, including 
model specifi cations and data availability for each cause-
specifi c model, can be found in the supplementary 
material of the GBD 2015 mortality and causes of death 
publication.12 We calculated normative life tables based on 
the lowest death rates for each age group among 
geographies with total populations greater than 5 million. 
We computed cause-specifi c YLLs by multiplying cause-
specifi c deaths by the life expectancy at the age of death 
(ie, 86·59 years at age 0 years; 23·79 years at age 65 years) 
from this normative life table, and then used the GBD 
world population age standard to calculate age-
standardised mortality rates and YLL rates.12
Our most commonly used analytic approach to 
estimate non-fatal health loss was DisMod-MR 2.1, a 
Bayesian meta-regression tool that synthesises diverse 
data sources to produce internally consistent estimates of 
incidence, prevalence, remission, and excess mortality. 
The use of other methods to estimate non-fatal health 
loss was determined by cause-specifi c data availability 
and epidemiological characteristics.24 Additional detail, 
including model specifi cations and data availability for 
each cause-specifi c model, can be found in the 
supplementary material of the GBD 2015 non-fatal 
publication.20 Each non-fatal sequela was estimated 
separately. We then applied a microsimulation framework 
to assess the occurrence of comorbidity in each age 
group, sex, geography, and year separately. Disability 
from comorbid conditions was apportioned to each of 
the contributing causes. GBD disability weights were 
based on population surveys with more than 
60 000 respondents, and previous studies show that 
disability weights do not signifi cantly vary across 
geographies, income, or educational attainment.25,26 In 
this study, disability weights are invariant over geography 
and time, although the distribution of sequelae, and 
therefore the severity and cumulative disability per case 
of a condition, can diff er by age, sex, geography, and year.
Estimation of DALYs, HALE, and corresponding 
uncertainty
DALYs are the sum of YLLs and YLDs as estimated in 
GBD 2015 for each cause, geography, age group, sex, and 
year.12,20 Using methods developed by Sullivan,7 we 
calculated HALE by age group within abridged multiple-
decrement life tables and estimates of YLDs per capita 
for each geography–age–sex–year from 1990 to 2015.8,10,27
For all results, we report 95% uncertainty intervals (UIs), 
which were derived from 1000 draws from the posterior 
distribution of each step in the estimation process. UIs are 
distinct from confi dence intervals, because confi dence 
For the interactive visualisation 
of GBD 2015 results see 
http://vizhub.healthdata.org/
gbd-compare/
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intervals only capture the uncertainty associated with 
sampling error, whereas uncertainty intervals provide a 
method for propagation of uncertainty from multiple 
sources including sampling, model estimation, and model 
specifi cation. 95% UIs represent the ordinal 25th and 
975th draw of the quantity of interest. For mortality and 
YLLs, UIs refl ect uncertainty that arises from sample sizes 
of studies used as data sources, adjustments to sources of 
all-cause mortality, parameter uncertainty in model 
estimation, and specifi cation uncertainty for all-cause and 
cause-specifi c models. For prevalence, incidence, and 
YLDs, UIs refl ect the uncertainty that arises from sample 
sizes of studies used as data sources, data adjustments 
from non-reference defi nitions, parameter uncertainty in 
model estimation, and uncertainty in the disability 
weights. In the absence of any direction information about 
the correlation between uncertainty in YLLs and YLDs, we 
assumed uncertainty in age-specifi c YLDs is independent 
of age-specifi c YLLs in DALYs and death rates in HALE. 
Epidemiological transition and relationship between 
DALYs, HALE, and SDI
We examined the relationship between DALYs, HALE, and 
the Socio-demographic Index (SDI).28 SDI was constructed 
based on the geometric mean of three indicators: income 
per capita, average years of schooling among people aged 
15 years or older, and the total fertility rate. SDI values were 
scaled to a range of 0 to 1, with 0 equalling the lowest 
income, lowest schooling, and highest fertility rate 
observed from 1980 to 2015, and 1 equalling the highest 
income, highest schooling, and lowest fertility rate 
assessed during that time. The average relationships 
between each summary health measure and SDI were 
estimated using spline regressions. These regressions 
were used to estimate expected values at each level of SDI. 
Additional detail on SDI computation and geography-
specifi c SDI values are available in the appendix (pp 4–5 
and pp 74–80).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had fi nal responsibility for 
the decision to submit for publication.
Results
Global trends for DALYs and HALE
Worldwide total DALYs due to Group 1 causes fell from 
1·2 billion (95% CI UI 1·2–1·2) in 1990, to 741·6 million 
(703·9–787·7) in 2015, whereas total DALYs due to NCDs 
increased from 1·1 billion (1·0–1·2), to 1·5 billion (1·3–1·7; 
fi gure 1; table 1). Total injury DALYs were relatively 
unchanged between 1990 and 2015. All-age DALY rates for 
NCDs changed little between 1990 and 2015, whereas they 
declined substantially for Group 1 causes. Taking into 
account population ageing, DALY rates for Group 1 causes 
and NCDs both decreased (fi gure 1). For injuries, 
reductions in all-age DALY rates and age-standardised 
DALY rates were similar between 1990 and 2015.
HALE at birth increased to 60·9 years for men and 
64·9 years for women in 2015, rising 2·9 years and 
3·5 years since 2005, respectively (table 2). The gap 
between life expectancy and HALE, which represents 
years of functional health lost, widened between 2005 
and 2015 from 7·7 years to 8·1 years for men, and from 
9·4 years to 10·0 years for women. Life expectancy at age 
65 years was 15·5 years for men and 18·5 years for 
women, while HALE was 11·9 years and 14·2 years for 
each sex, respectively (table 2).
Global causes of DALYs
In 2015, Group 1 causes accounted for 30·1% (95% UI 
28·6–31·7%) of global DALYs, with NCDs leading to 
59·7% (57·8–61·5) and injuries to 10·1% (9·5–10·7; 
table 1). Since 2005, DALYs due to many of the world’s 
leading communicable causes substantially declined, yet 
burden increased for a subset of infectious diseases. Age-
standardised DALY rates from HIV/AIDS and malaria 
each fell by more than 40% and lower respiratory 
infections and diarrhoeal diseases had decreases in total 
and age-standardised rates of DALYs of more than 20% 
(table 1). From 2005 to 2015, reductions in both total and 
age-standardised DALY rates due to tetanus and measles 
surpassed 50% and 70%, respectively. African trypano-
somiasis, a disease targeted for elimination, saw both 
total DALYs and age-standardised rates fall by more than 
70% since 2005. DALY rates substantially fell for all types 
of hepatitis, with age-standardised DALY rates from acute 
hepatitis A declining by more than 35% by 2015. However, 
both total DALYs and age-standardised DALY rates from 
dengue increased by more than 50%. Although the west 
African Ebola virus outbreak peaked in 2014,29 Ebola virus 
disease still caused substantial DALYs in 2015 (table 1). 
Maternal disorders signifi cantly declined from 2005 to 
2015, with total DALYs and age-standardised rates each 
falling by more than 20%. Reductions in the global 
burden of neonatal disorders were somewhat less 
pronounced; for instance, the number of DALYs due to 
neonatal sepsis was largely unchanged (table 1).
In 2015, cardiovascular diseases, cancers, and mental 
and substance use disorders were among the leading 
causes of NCD burden (table 1). For many NCDs, including 
most cardiovascular causes and most cancers, total DALYs 
increased but age-standardised DALY rates declined. 
Nearly all neurological disorders increased in total DALYs, 
including Alzheimer’s disease and other dementias, which 
rose by more than 30%, whereas age-standardised rates 
either moderately decreased (eg, Alzheimer’s disease and 
other dementias) or were relatively unchanged (eg, 
Parkinson’s disease). Total DALYs from low back and neck 
pain also increased, rising by more than 17%. Cirrhosis 
caused more DALYs in 2015 than in 2005, although age-
standardised DALY rates signifi cantly fell. A similar overall 
See Online for appendix
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trend was found for diabetes and chronic kidney disease, 
with all aetiologies apart from chronic kidney disease due 
to diabetes, showing signifi cant declines in age-
standardised DALY rates amid rising total DALYs. For 
other NCDs, namely those associated with skin diseases, 
sensory conditions, and oral disorders, total DALYs 
signifi cantly increased from 2005 to 2015, and age-
standardised DALY rates either somewhat increased or did 
not signifi cantly change since 2005. Age-standardised 
DALY rates due to chronic obstructive pulmonary disease 
fell by more than 20% from 2005 to 2015, while those due 
to asthma decreased by almost 17%. Peptic ulcer disease, a 
leading cause of digestive disease burden, saw marked 
reductions in total DALYs and age-standardised DALY 
rates, with the latter decreasing by nearly 30% (table 1).
A number of NCDs signifi cantly increased in terms 
of total burden and age-standardised DALY rates. 
Osteoarthritis was the most notable example, with total 
DALYs rising by 35% and age-standardised DALY rates 
by 4% between 1990 and 2015. Major depressive disorders 
and drug use disorders, particularly of opioids and 
cocaine, both increased in total DALYs and age-
standardised rates; however, age-standardised DALY 
rates from alcohol use disorders dropped by 19%. Total 
DALYs and age-standardised DALY rates from chronic 
kidney disease due to diabetes also signifi cantly increased 
by 2015. Male and female infertility accounted for a 
relatively small fraction of NCDs, but burden due to both 
causes increased signifi cantly since 2005. Oral disorders 
and sense organ diseases also had increased total DALYs, 
whereas age-standardised DALY rates were relatively 
unchanged since 2005.
Unintentional injuries and transport injuries each saw 
age-standardised DALY rates signifi cantly decrease (20% 
and 17%, respectively). Road injury burden signifi cantly 
declined from 2005, with age-standardised DALY rates 
falling by 18% by 2015. Among unintentional injuries, 
drowning had the largest reduction in both total burden 
(26%) and age-standardised DALY rates (32%). Age-
standardised DALY rates from self-harm and interpersonal 
violence both fell by more than 16% since 2005. DALYs 
due to forces of nature, war, and legal intervention 
increased from 2005 to 2015, although not signifi cantly; 
this rise was primarily driven by escalated violence and 
war in the Middle East. Despite still causing major health 
loss in 2015, forces of nature caused far fewer DALYs than 
in 2005, mainly because there were no large-scale losses of 
life like that seen in the 2005 earthquake that killed more 
than 70 000 people in India and Pakistan.
Changes in leading causes of disease burden over time
In 1990, lower respiratory infections, preterm birth 
complications, and diarrhoeal diseases were the three 
leading causes of global DALYs; by 2015, only lower 
respiratory infections remained in the leading three 
(fi gure 2). Many Group 1 causes had signifi cant declines 
for total burden, as well as all-age DALY rates and age-
standardised DALY rates, for both time periods; these 
causes included tuberculosis, meningitis, diarrhoeal 
diseases, protein-energy malnutrition, preterm birth 
complications, tetanus, and measles. Such reductions 
across measures of DALYs contributed to downward shifts 
in relative ranks for most Group 1 causes over time. 
Malaria and HIV/AIDS both diverged from this trend, 
Figure 1: Trends from 1990 to 2015, by GBD Level 1 cause, in global DALYs (A), crude DALY rates (B), and age-standardised DALY rates (C)
The diff erence in trends between (A) and (B) is caused by population growth and the diff erence between (B) and (C) is caused by changes in the percentage 
distribution of the population by age. Shaded areas show 95% uncertainty intervals. DALYs=disability-adjusted life-years. 
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
All causes 2 553 306·8
(2 373 137·6 to 
2 756 328·0)
2 464 895·4




(38 640·8 to 
44 850·4)
34 445·7




neonatal, and nutritional diseases
968 014·5
(931 809·4 to 1 012 327·9)
741 595·9




(13 766·0 to 14 955·1)
10 007·2
(9 498·5 to 10 629·3)
–30·0
(–31·6 to –28·5)*
HIV/AIDS and tuberculosis 148 685·6
(141 013·7 to 160 635·2)
106 991·8











(43 196·4 to 60 348·2)
40 302·2










(94 515·6 to 103 953·2)
66 689·5










(15 512·5 to 22 015·1)
11 621·9









HIV/AIDS resulting in other 
diseases
79 589·0
(74 869·9 to 85 308·1)
55 067·6









Diarrhoea, lower respiratory,  and 
other common infectious diseases
333 534·0
(317 202·5 to 351 569·5)
242 875·8










Diarrhoeal diseases 98 394·2
(90 909·6 to 106 634·4)
71 589·5






(908·1 to 1 052·7)
–34·0
(–39·3 to –28·4)*
Intestinal infectious diseases 15 062·4
(8 707·5 to 24 651·4)
12 632·0









Typhoid fever 12 543·9
(6 953·1 to 21 143·4)
10 575·6



































Lower respiratory infections 135 293·2
(127 083·7 to 143 499·4)
103 048·6









Upper respiratory infections 2 661·2
























(24 170·2 to 32 237·2)
25 394·6
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
(Continued from previous page)
Neglected tropical diseases 
and malaria
116 583·6
(96 865·6 to 137 551·5)
79 212·2











(73 336·5 to 107 546·9)
55 769·6







































































































































































































































































(31 640·5 to 
31 681·3)*












Maternal disorders 20 797·1
(19 462·4 to 22 290·3)
16 282·0










(4 902·4 to 6 402·8)
4645·8
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
(Continued from previous page)


























































































Neonatal disorders 239 098·4
(232 872·7 to 246 048·9)
197 924·8






(2551·0 to 2 729·5)
–21·7
(–23·6 to –20·0)*
Neonatal preterm birth 
complications
99 050·0
(92 118·6 to 110 250·8)
74 833·6









Neonatal encephalopathy due to 
birth asphyxia and trauma
79 423·6
(72 215·4 to 87 185·6)
67 856·5









Neonatal sepsis and other 
neonatal infections
30 510·1
(21 830·7 to 40 329·6)
30 454·5























Other neonatal disorders 23 687·6
(17 420·2 to 30 795·3)
20 276·2









Nutritional defi ciencies 84 133·3
(65 215·4 to 108 480·6)
76 517·1






(795·9 to 1 363·6)
–16·8
(–22·4 to –11·7)*
Protein-energy malnutrition 26 655·2
(21 449·8 to 32 723·9)
21 094·0

































Iron-defi ciency anaemia 52 951·3
(36 342·0 to 74 873·5)
51 217·1





















Other communicable, maternal, 
neonatal, and nutritional 
diseases
25 182·6
(20 002·2 to 31 397·3)
21 792·2









Sexually transmitted diseases 
excluding HIV
12 378·7
(7 831·6 to 18 396·6)
10 330·9
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15









































































Non-communicable diseases 1 322 207·9
(1 181 179·7 to 
1 471 448·8)
1 473 508·2




(20 898·5 to 
25 689·0)
21 062·4




(183 699·7 to 191 539·2)
209 359·2













































Oesophageal cancer 10 665·4
(10 313·5 to 11 043·9)
9 854·4









Stomach cancer 18 665·9
(18 186·3 to 19 175·5)
17 439·6









Colon and rectum cancer 14 409·5
(14 108·0 to 14 779·0)
17 026·6









Liver cancer 19 643·6
(16 871·4 to 20 641·2)
20 578·0

































































































Tracheal, bronchus, and lung 
cancer
31 802·0
(31 117·2 to 32 516·2)
36 419·5
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
(Continued from previous page)
Breast cancer 12 939·2
(12 181·7 to 13 828·7)
15 410·6






































































































































































(10 956·3 to 11 683·7)
12 040·4


























































(9023·1 to 10 351·7)
11 789·9









Cardiovascular diseases 326 252·4
(318 365·8 to 334 285·8)
347 528·9









Rheumatic heart disease 11 594·7
(10 668·9 to 12 707·4)
10 513·2









Ischaemic heart disease 147 780·0
(144 845·9 to 151 651·5)
164 020·4









Cerebrovascular disease 118 566·2
(115 776·1 to 121 419·2)
118 626·7









Ischaemic stroke 44 104·6
(42 363·3 to 45 822·3)
45 208·5









Haemorrhagic stroke 74 461·5
(72 176·9 to 76 874·3)
73 418·2









Hypertensive heart disease 14 852·4
(13 919·4 to 16 052·6)
17 484·6
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15































































Other cardiovascular and 
circulatory diseases
15 032·7
(13 427·8 to 16 820·7)
16 890·7









Chronic respiratory diseases 97 356·3
(90 607·8 to 104 559·9)
97 451·8









Chronic obstructive pulmonary 
disease
63 773·8
(60 981·4 to 66 186·6)
63 850·4










(816·2 to 1 168·6)
1 099·6


























































(21 268·1 to 33 122·5)
26 168·8





































Cirrhosis and other chronic liver 
diseases
37 101·5
(35 722·1 to 39 385·8)
38 973·3









Cirrhosis and other chronic liver 
diseases due to hepatitis B
10 297·6
(9 495·9 to 11 233·5)
10 754·7









Cirrhosis and other chronic liver 













Cirrhosis and other chronic liver 
diseases due to alcohol use
10 093·5
(9 424·0 to 10 841·4)
10 997·4









Cirrhosis and other chronic liver 













Digestive diseases 41 351·8
(37 701·8 to 45 778·3)
42 189·1









Peptic ulcer disease 10 164·0
(9220·6 to 11 279·2)
8894·4
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
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Neurological disorders 74 456·9
(58 081·0 to 93 693·7)
87 082·1









Alzheimer’s disease and other 
dementias
17 905·9
(15 147·4 to 20 849·2)
23 779·2






















(10 694·5 to 15 020·3)
12 417·9


































(17 584·9 to 42 479·8)
32 898·8













































Mental and substance use 
disorders
141 375·1
(105 843·7 to 178 447·3)
162 442·3










(9 635·3 to 16 203·0)
15 516·1









Alcohol use disorders 11 566·7
(9 617·6 to 13 834·9)
11 194·3









Drug use disorders 13 671·4
(11 292·6 to 16 046·0)
16 909·5









Opioid use disorders 9864·0
(8127·4 to 11516·8)
12 068·1









Cocaine use disorders 729·3
(558·4 to 902·4)
999·3













































Depressive disorders 45 916·0
(31 684·6 to 61 591·2)
54 255·4









Major depressive disorder 37 544·8
(24 983·0 to 51 134·6)
44 224·4










(5 537·6 to 11 983·7)
10 031·0
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2005 2015 Percentage 
change,
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change,
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Anxiety disorders 21 474·8
(14 666·7 to 29 339·6)
24 643·0













































Autistic spectrum disorders 8949·8
(5978·1 to 12 300·4)
10 051·5

























































































Diabetes, urogenital, blood, and 
endocrine diseases
122 917·1
(106 347·2 to 142 775·0)
146 780·6









Diabetes mellitus 49 724·5
(41 868·2 to 58 982·1)
64 134·5




(772·1 to 1 076·0)
925·8















Chronic kidney disease 29 488·3
(26 950·4 to 31 604·2)
35 259·7























Chronic kidney disease due to 
hypertension
10 366·1
(9 400·8 to 10 985·1)
12 737·4
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
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(16 303·9 to 25 551·6)
20 604·4













































































































Musculoskeletal disorders 123 801·0
(90 494·0 to 163 616·5)
148 986·5






















(6666·3 to 13 106·3)
12 886·2









Low back and neck pain 80 053·5
(57 147·1 to 108 282·6)
94 941·5









Low back pain 51 243·0
(36 375·0 to 70 714·6)
60 074·8




(605·3 to 1 176·4)
829·5
(589·2 to 1 138·3)
–2·6
(–3·2 to –2·0)*
Neck pain 28 810·5
(19 224·7 to 39 466·1)
34 866·7





















Other musculoskeletal disorders 27 917·2
(19 404·3 to 38 408·8)
33 482·6












(132 096·5 to 221 007·5)
192 712·9









Congenital anomalies 57 594·6
(49 489·5 to 69 397·4)
58 355·3





















Congenital heart anomalies 26 778·2
(22 186·7 to 31 821·1)
25 706·4
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2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
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Other congenital anomalies 19 039·2
(16 026·4 to 23 290·1)
21 708·1









Skin and subcutaneous diseases 42 069·1
(27 826·1 to 62 299·6)
47 222·7







































































































































































Sense organ diseases 54 708·4
(38 076·6 to 75 346·3)
68 515·2




(694·9 to 1 361·8)
999·9










































(7737·6 to 18 905·4)
14 593·8









Age-related and other hearing 
loss
32 119·0
(21 992·4 to 44 438·1)
40 596·8
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All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15
(Continued from previous page)
Oral disorders 13 868·2
(8387·2 to 21 285·6)
16 969·6




















































































(245 566·5 to 278 621·5)
249 791·3









Transport injuries 77 146·4
(73 768·7 to 80 734·9)
72 365·5









Road injuries 71 941·1
(68 596·1 to 75 312·5)
67 270·4









Pedestrian road injuries 27 185·9
(25 567·5 to 29 487·1)
24 491·1





















Motorcyclist road injuries 13 655·4
(12 181·3 to 14 651·4)
13 686·2









Motor vehicle road injuries 26 257·7
(24 307·0 to 28 943·8)
24 460·3

































Unintentional injuries 118 001·9 
(105 534·5 to 129 998·5)
107 990·9










(20 767·3 to 27 587·9)
26 101·6










(20 715·5 to 25 812·8)
17 864·3









Fire, heat, and hot substances 11 737·6
(9 928·4 to 12 948·0)
10 274·1





















Exposure to mechanical forces 13 753·4
(12 020·2 to 15 236·7)
13 118·4
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with each recording large increases in burden from 1990 
to 2005, but by 2015, all measures of DALYs and relative 
ranks for malaria and HIV/AIDS had fallen markedly. 
Trends for NCDs and injuries, both in terms of ranks and 
changes in disease burden, were more varied. Between 
1990 and 2005, total DALYs and all-age DALY rates 
signifi cantly increased for many NCDs, including 
ischaemic heart disease, low back and neck pain, lung 
cancer, chronic kidney disease, and migraine. For these 
NCDs, their relative ranks also climbed by 2005, yet their 
age-standardised DALY rates either signifi cantly decreased 
or remained relatively unchanged, refl ecting the eff ects of 
changes in population age structure. This pattern 
continued through 2015 for many NCDs, and was further 
exemplifi ed by Alzheimer’s disease and other dementias 
as it rose to the 29th leading cause of global DALYs amid a 
signifi cant decrease in age-standardised DALY rates. From 
1990 to 2005, all three measures of DALYs signifi cantly 
increased for a subset of NCDs (ie, sense organ diseases, 
diabetes, depressive disorders, and other musculoskeletal 
disorders), which contributed to their rises in relative 
ranking. More heterogeneous patterns emerged for 
injuries; for instance, road injuries and interpersonal 
violence each rose in refl ective ranks from 2005 to 2015, 
despite signifi cant reductions in total DALYs, all-age DALY 
rates, and age-standardised DALY rates from each cause.
For at least one of their leading causes of DALYs in 2015, 
most age groups under 40 years old had a more than 31% 
decrease in total burden (fi gure 3). The causes for which 
DALYs largely declined included lower respiratory 
infections, diarrhoeal diseases, malaria, preterm birth 
complications, and drowning among children younger 
than 5 years, and HIV/AIDS and malaria for people 
between the ages of 5 years and 40 years. Increases in 
cause-specifi c DALYs varied more by age, with rising 
DALYs due to depressive disorders and drug use disorders 
for populations at age 20–30 years. DALYs from low back 
and neck pain increased since 2005 for many age groups. 
All-age DALYs (thousands) Age-standardised rate (per 100 000)
2005 2015 Percentage 
change,
2005–15
2005 2015 Percentage 
change,
2005–15



























Pulmonary aspiration and 





















































Other unintentional injuries 13 348·6
(11 406·7 to 15 619·1)
12 240·0









Self-harm and interpersonal 
violence
58 615·7
(52 794·8 to 60 379·5)
55 719·4










(31 467·1 to 37 112·4)
34 260·9









Interpersonal violence 22 796·5
(20 747·8 to 23 566·7)
21 458·5













































Forces of nature, war, and legal 
intervention
9320·3
(6951·1 to 11 778·4)
13 715·5



































Data in parentheses are 95% uncertainty intervals. DALYs=disability-adjusted life-years. G6PD=glucose-6-phosphate dehydrogenase. *Percentage changes that are statistically signifi cant.
Table 1: Global all-age DALYs and age-standardised DALY rates in 2005 and 2015 with median percentage change between 2005 and 2015 for all causes
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2005, at birth 2015, at birth 2015, at age 65 years
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For people 60 years and older, several causes, including 
ischaemic heart disease, chronic kidney disease, diabetes, 
hearing loss, and Alzheimer’s disease and other 
dementias, ranked among the leading causes of DALYs in 
2015 and caused more DALYs than in 2005. 
Regional and country-specifi c HALE
HALE at birth was highest for men in Singapore 
(72·3 years [95% UI 70·1–74·2]) and for women in 
Andorra (76·3 years [72·8–79·4]) in 2015. It was lowest in 
Lesotho for both men (39·1 years [34·3–44·7]) and women 
(43·8 years [37·9–49·8]; table 2; appendix p 12). HALE at 
birth in 2015 exceeded 70 years in only 14 geographies for 
men, while 59 countries and territories surpassed this 
threshold for women. 13 countries and territories had 
HALE lower than 50 years for either sex. Since 2005, 
121 countries and territories had signifi cant increases in 
HALE at birth for men and 139 for women, led in both 
cases by Zimbabwe, whereas HALE at birth worsened for 
two countries (Syria and Libya) driven mainly by decreases 
in life expectancy (table 2). HALE at age 65 years was 
highest in Andorra for both men (15·2 years 
[UI 13·9–16·3]) and women (19·4 years [17·8–20·8]) in 
2015, whereas the lowest HALE for men was in Lesotho 
(6·9 years [5·2–9·4]) and for women in Afghanistan 
(6·9 years [5·8–8·2]).
Epidemiological transition
HALE at birth increased continuously and in a largely 
linear manner with increasing SDI for both sexes 
(fi gure 4A). At a SDI of 0·20, average HALE was 46·2 years 
for men and 47·1 years for women; by a SDI of 0·90, 
average HALE was 69·8 years for men and 73·8 years for 
women. Among high SDI regions, North America was the 
furthest below expected HALE at birth for both sexes, 
whereas high-income Asia Pacifi c remained above 
expected HALE at birth for both sexes and over time. In 
Australasia, male HALE was consistently close to expected 
levels, whereas female HALE remained below expected 
levels since 1990. With the exception of the Caribbean in 
2010 (the year of the Haitian earthquake) HALE at birth 
throughout Latin America and the Caribbean was generally 
higher than expected for both sexes. HALE at birth also 
exceeded expectations in east Asia and north Africa and 
the Middle East. By contrast, Oceania steadily remained 
below expected levels of HALE, and all regions within the 
central Europe, eastern Europe, and central Asia GBD 
super-region had HALE lower than expected over time, 
particularly for men. HALE trends in sub-Saharan Africa 
were heavily infl uenced by the HIV/AIDS epidemic, 
particularly in southern sub-Saharan Africa, where HALE 
was well below expected levels. Notably, after lagging below 
expected levels of HALE before 2005, eastern sub-Saharan 
Africa posted average HALE for women that exceeded 
expected levels. Less pronounced increases occurred for 
men in eastern sub-Saharan Africa, as HALE essentially 
equalled expected levels only around 2010 (fi gure 4A).
Years of functional health lost on average increased as 
countries developed (fi gure 4B). Among high-income 
regions, all regions except for high-income Asia Pacifi c 
consistently exceeded expected levels of functional health 
loss over time, and women generally experienced a 
higher gap than men. South Asia, north Africa and the 
Middle East, and central sub-Saharan Africa had 
generally higher-than-expected functional health loss, 
whereas a number of regions, including Oceania, 
southeast Asia, and east Asia, all recorded smaller gaps 
between life expectancy and HALE than was expected.
The ratio of years of functional health loss to life 
expectancy, the proportion of life expectancy spent with 
disability, declined slightly with increasing SDI (fi gure 4C). 
Among men and women, central sub-Saharan Africa had 
the highest proportion of life spent with disability in 2015, 
although high-income North America had the largest 
diff erence between observed and expected levels for that 
year. For both sexes, several regions showed higher-than-
expected proportions of life expectancy spent in ill health 
(eg, south Asia, north Africa and the Middle East, and 
2005, at birth 2015, at birth 2015, at age 65 years
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Data in parentheses are 95% uncertainty intervals. HALE=healthy life expe ctancy. SDI=Socio-demographic Index.
Table 2: Global, regional, and national or territory life expectancy and HALE at birth, by sex, in 2005 and 2015, and HALE at age 65, by sex, in 2015
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Australasia), whereas others experienced lower-than-
expected levels over time (eg, southeast Asia, east Asia, 
eastern sub-Saharan Africa, and southern Latin America).
Expected age-standardised YLL rates for many 
communicable causes and neonatal conditions declined 
profoundly as SDI increased (fi gure 5A). At the same time, 
age-standardised YLD rates for the leading causes of YLDs 
such as mental and substance abuse disorders and 
musculoskeletal disorders demonstrate relatively little 
change. At higher SDIs, the composition of disease burden 
shifted toward YLDs as the primary driver of burden, 
mainly due to the diff erential pace of change. The combined 
eff ect of the change in age-specifi c rates and age-structure 
change that occur with development is shown in fi gure 5B, 
which provides expected all-age YLL and YLD rates for 
Level 2 causes. Demographic shifts in age-structure 
potentiate and accelerate the transition from Group 1 
conditions toward NCDs in terms of the composition of the 
burden of disease that health systems must handle. Of 
note, from an SDI of 0·8 onwards further declines in the 
age-standardised rates are matched or exceeded by 
increases in population age structure so that all-age rates 
for YLDs actually increase, as do YLL rates for some causes 
such as neurological conditions. These characterisations of 
the epidemiological transition demonstrate the double 
burden of communicable diseases and NCDs for 
populations with an SDI in the intermediate range.
Observed versus expected total and cause-specifi c burden
In 2015, the Maldives and Nicaragua had the lowest ratios 
of observed to expected all-ages DALY rates; many countries 
throughout Latin America also had lower-than-expected all-
ages DALY rates (fi gure 6). Other regions where observed 
all-ages DALY rates fell below expected levels, included 
western Europe (eg, Portugal, Spain, France, Italy, and 
Sweden); western sub-Saharan Africa (eg, Burkina Faso, 
Figure 2: Leading 30 Level 3 causes of global DALYs for both sexes combined, 1990, 2005, 2015, with percentage change in number of DALYs, and all-age, and age-standardised rates
Causes are connected by lines between time periods; solid lines are increases and dashed lines are decreases. For the time period of 1990 to 2005 and for 2005 to 2015, three measures of change are 
shown: percent change in the number of DALYs, percent change in the all-age DALY rate, and percent change in the age-standardised DALY rate. Statistically signifi cant changes are shown in bold. 
DALYs=disability-adjusted life-years. COPD=chronic obstructive pulmonary disease.
















































































































































































































2 Neonatal preterm birth 2 Lower respiratory infection 2 Cerebrovascular disease
3 Diarrhoeal diseases 3 Cerebrovascular disease 3 Lower respiratory infection
4 Ischaemic heart disease 4 Neonatal preterm birth 4 Low back and neck pain
5 Cerebrovascular disease 5 HIV/AIDS 5 Neonatal preterm birth
6 Neonatal encephalopathy 6 Diarrhoeal diseases 6 Diarrhoeal diseases
7 Malaria 7 Malaria 7 Sense organ diseases
8 Measles 8 Low back and neck pain 8 Neonatal encephalopathy
9 Congenital anomalies 9 Road injuries
10 COPD 10 Road injuries 10 HIV/AIDS
11 Road injuries 11 COPD 11 Diabetes
12 Low back and neck pain 12 Congenital anomalies 12 COPD
13 Tuberculosis 13 Sense organ diseases 13 Congenital anomalies
14 Iron-deficiency anaemia 14 Iron-deficiency anaemia 14 Malaria
15 Protein-energy malnutrition 15 Tuberculosis 15 Depressive disorders
16 Sense organ diseases 16 Diabetes 16 Iron-deficiency anaemia
17 Drowning 17 Depressive disorders 17 Skin diseases
18 Meningitis 18 Skin diseases 18 Tuberculosis
19 Depressive disorders 19 Self-harm 19 Lung cancer
20 Skin diseases 20 Lung cancer 20 Chronic kidney disease
21 Self-harm 21 Neonatal sepsis 21 Self-harm
22 Other neonatal 22 Chronic kidney disease 22 Other musculoskeletal
23 Asthma 23 Migraine 23 Migraine
24 Diabetes 24 Meningitis 24 Neonatal sepsis
25 Neonatal sepsis 25 Other musculoskeletal 25 Asthma
26 Tetanus 26 Asthma 26 Falls
27 Lung cancer 27 Protein-energy malnutrition 27 Meningitis
28 Falls 28 Measles 28 Anxiety disorders
29 Migraine 29 Drowning 29 Alzheimer’s disease
30 Chronic kidney disease 30 Falls 30 Interpersonal violence
31 Other neonatal31 Interpersonal violence 31 Protein-energy malnutrition
32 Interpersonal violence34 Other musculoskeletal 34 Other neonatal
33 Anxiety disorders37 Anxiety disorders 35 Drowning
37 Alzheimer’s disease42 HIV/AIDS 81 Measles
72 Tetanus49 Alzheimer’s disease 100 Tetanus
9 Neonatal encephalopathy
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Niger, and Senegal); eastern sub-Saharan Africa (eg, 
Burundi and Ethiopia); north Africa and the Middle East 
(eg, Jordan, Saudi Arabia, and Turkey); east Asia (eg, 
China); and a subset of countries in South and 
Southeast Asia (eg, Bangladesh, Sri Lanka, and Vietnam). 
By contrast, observed all-ages DALY rates exceeded expected 
levels in southern sub-Saharan Africa, much of central Asia 
and eastern Europe, and a number of countries in central 
sub-Saharan Africa. Notably, observed all-ages DALY rates 
surpassed expected levels in the USA.
Ischaemic heart disease and stroke were the leading two 
causes of DALYs worldwide in 2015, and 106 geographies 
also had one of these diseases as the leading cause of 
DALYs that year (fi gure 7). Four GBD super-regions 
showed deviations from this trend: Latin America and the 
Caribbean, where diabetes and interpersonal violence 
often resulted in the most DALYs; north Africa and the 
Middle East, where war was a primary cause of burden; 
south Asia, where neonatal disorders often ranked among 
the leading causes of DALYs; and sub-Saharan Africa, 
where HIV/AIDS or malaria was the leading driver of 
disease burden in 29 geographies.
Stroke resulted in the most countries (94) having lower 
observed DALYs than expected based on their SDI. Other 
leading causes for which observed DALYs were well below 
expected levels included ischaemic heart disease 
particularly in Latin America, east Asia, and southeast 
Asia; road injuries in north Africa and the Middle East; 
and lower respiratory infections and diarrhoeal diseases in 
sub-Saharan Africa. Many high-income countries and 
territories also had lower-than-expected DALYs from 
ischaemic heart disease and Alzheimer’s disease and other 
dementias. Road injuries accounted for lower burden than 
expected in 52 countries and territories, especially in 
Colombia. Although many Group 1 causes remained 
among the leading causes of DALYs, observed levels were 
often lower than expected on the basis of SDI (eg, lower 
respiratory infections in Ethiopia, diarrhoeal diseases in 
Afghanistan, and preterm birth complications in Kenya).
By contrast, diabetes was a leading cause for which 
observed burden exceeded expected levels in many 
geographies, especially in Oceania and the Caribbean. 
Observed DALYs due to chronic obstructive pulmonary 
disease were higher than expected in 30 geographies, as 
were those due to liver cancer and lung cancer for a subset 
of countries and territories. Drug use disorders led to more 
observed DALYs than expected in many high-income 
countries in 2015, particularly in the USA and Australia. 
A similar pattern occurred for self-harm, cirrhosis, alcohol 
use disorders, and drug use disorders throughout eastern 
Europe, and most prominently in Russia. Interpersonal 
violence was among the leading two causes of DALYs for 
six of 11 countries in central and tropical Latin America 
(Brazil, Colombia, El Salvador, Guatemala, Honduras, and 
Figure 3: Leading ten Level 3 causes of global age-specifi c DALYs in 2015
Each cause is coloured by the percentage change in age-specifi c DALYs from 2005 to 2015. NN Preterm=neonatal preterm birth complications. NN Sepsis=neonatal sepsis and other neonatal infections. 
LRI=lower respiratory infections. Iron=iron-defi ciency anaemia. HIV=HIV/AIDS. Back & neck=low back and neck pain. IHD=ischaemic heart disease. NN Enceph=neonatal encephalopathy due to birth asphyxia 
and trauma. Diarrhoea=diarrhoeal diseases. Skin=skin and subcutaneous diseases. Depression=depressive disorders. Stroke=cerebrovascular disease. Congenital=congenital anomalies. Diabetes=diabetes 
mellitus. COPD=chronic obstructive pulmonary disease. Alzheimer’s=Alzheimer’s disease and other dementias. PEM=protein-energy malnutrition. Conduct=conduct disorder. Sense=sense organ diseases. 
Other NN=other neonatal disorders. Intest inf=intestinal infectious diseases. Violence=interpersonal violence. NN Haemol=haemolytic disease and other neonatal jaundice. Anxiety=anxiety disorders. 
TB=tuberculosis. Lung C= lung, bronchial, and tracheal cancers. STD=sexually transmitted diseases excluding HIV. Haemog=haemoglobinopathies and haemolytic anaemias. CKD=chronic kidney disease. 
Other MSK=other musculoskeletal disorders. Drugs=drug use disorders. Stomach C=stomach cancer. HTN HD=hypertensive heart disease. GBD=Global Burden of Disease. DALYs=disability-adjusted life-years. 
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Venezuela), and each had observed burden far surpassing 
expected levels. Throughout sub-Saharan Africa, HIV/
AIDS and malaria resulted in far more DALYs than 
expected based on SDI.
Heterogeneous trends across and within regions 
emerged in terms of both leading causes of DALYs and 
ratios of observed to expected levels. For instance, south 
Asia’s disease burden landscape diverged from global 
patterns, with both ischaemic heart disease and neonatal 
disorders ranking among some of the leading causes of 
burden and often resulting in higher-than-expected 
DALYs (fi gure 7). Stroke and lower respiratory infections 
resulted in fewer DALYs than expected for most countries 
in south Asia, yet other causes exacted more DALYs than 
expected on the basis of SDI (eg, tuberculosis in India 
and drowning in Bangladesh). Further, the 2015 Nepal 
earthquake resulted in forces of nature being its leading 
cause of DALYs that year. Many countries in central Asia 
experienced observed DALYs that surpassed expected 
levels due to both Group 1 causes (eg, lower respiratory 
Figure 4: Co-evolution of HALE (A), functional health lost (life expectancy minus HALE; B), and life expectancy spent with disability (life expectancy minus HALE, divided by HALE; C) with 
SDI globally and for GBD regions, 1990 to 2015
Coloured lines show global and region values for each metric. Each point in a line represents 1 year starting at 1990 and ending at 2015. In all regions, SDI has increased year on year so progress in SDI is 
associated with later years for a given region. The black lines indicate trajectories for each geography expected on the basis of SDI alone. GBD=Global Burden of Disease. SDI=Socio-demographic Index. 
HALE=healthy life expectancy. DALYs=disability-adjusted life-years.
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Figure 5: Expected relationship between age-standardised YLL and YLD rates and SDI (A) and all-age YLL and YLD rates (per 100 000) and SDI (B) for 21 GBD 
Level 2 causes
These stacked curves represent the average relationship between SDI and each cause observed across all geographies over the time period 1990 to 2015. In each 
fi gure, the y axis goes from lowest SDI to highest SDI. The left side shows rates for YLLs and the right side shows rates for YLDs; higher rates are further from the 
midline. The diff erence between (A) and (B) is the eff ect of shifts in population age structure expected with SDI. GBD=Global Burden of Disease. 
SDI=Socio-demographic Index. YLDs=years lived with disability. YLLs=years of life lost.
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infections, preterm birth complications, and neonatal 
encephalopathy) and NCDs such as hypertensive heart 
disease. War was the leading cause of DALYs in fi ve 
countries in north Africa and the Middle East in 2015, 
including Afghanistan, Iraq, Libya, Syria, and Yemen. 
Although neonatal sepsis frequently led to higher-than-
expected DALYs in sub-Saharan Africa, burden from 
preterm birth complications fell below expected levels, 
on the basis of SDI, in most countries. Notably, NCDs 
such as diabetes ranked among the leading ten causes of 
DALYs for a subset of countries in sub-Saharan Africa 
(eg, South Africa), whereas nutritional defi ciencies also 
remained among leading causes of burden in others (eg, 
Ghana and Zimbabwe); in both instances, observed 
DALYs generally exceeded expected levels.
Discussion
GBD 2015 results show that the world has become 
healthier in the past 25 years. Yet, this progress has not 
been universal. From 1990 to 2015, global HALE at birth 
increased from 56·7 years to 62·8 years, with 191 of 
199 countries or territories recording improved HALE. 
Since 1990, global HALE at age 65 years also improved by 
1·8 years, with an increase in 179 countries or territories. 
The global number of years of functional health lost grew 
during this time, from 8·2 years to 9·1 years. With YLL 
rates falling at a much faster pace than YLD rates, non-
fatal health loss accounted for an increasing proportion of 
global DALYs, rising from 21·2% in 1990, to 32·1% in 
2015. Worldwide progress was largely driven by rapid 
reductions in DALYs from communicable, maternal, 
neonatal, and nutritional diseases, although declines in 
age-standardised DALY rates from NCDs and injuries also 
contributed to overarching gains. Despite reductions in 
age-standardised DALY rates, 137 causes had statistically 
signifi cant increases in total DALYs since 2005, a trend 
with extensive implications for health systems. Mental and 
substance use disorders, musculoskeletal disorders, and 
a range of other conditions including idiopathic 
developmental intellectual disability, vision and hearing 
impairment, and neurological disorders all saw rising 
disease burden since 2005, and few saw any evidence of 
declining age-specifi c YLD rates.
Considerable research and policy attention has 
considered the existence of compression of morbidity, or 
whether people live healthier lives as their lifespans 
extend.30 Beyond its profound consequences for fi nancing 
health systems, compression of morbidity has 
considerable implications for societal structures and 
expectations about longevity of careers or timing of 
Figure 6: Ratio of observed versus expected age-standardised DALY rates (per 100 000) on the basis of SDI alone for both sexes combined, 2015
Ratios are colour-coded in terms of the magnitude of diff erences between observed and expected all-ages DALY rates. Blues indicate much lower observed DALYs than expected levels based on SDI, 
whereas reds refl ect that observed DALYs far exceed expected levels given SDI. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
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retirement. Compression can be interpreted in both 
absolute and relative terms. Absolute compression implies 
that as people live longer lives, they lose fewer years due to 
functional health loss, whereas relative compression 
implies that as people live longer lives, the ratio of years of 
functional health lost to life expectancy declines. Although 
some evidence shows that compression occurs among 
people with specifi c diseases such as diabetes and 
dementia,31,32 national studies show more mixed results.33–35 
This might not be surprising, as most national studies 
rely on self-reported health status and chronic conditions, 
which are then further complicated by variations in how 
individuals use the response scales and profound framing 
eff ects.36–39 By contrast, the GBD study provides a more 
comprehensive and comparable assessment of changes in 
functional health status by synthesising many types of 
data, by cause, and applying standardised disability 
weights to refl ect the public’s average views of severity of 
diff erent conditions. GBD 2015 results unequivocally 
show that as life expectancy increases, people spend more 
time with reduced functional health status, and thus 
absolute expansion of morbidity has occurred. This trend 
is driven by marked declines in age-specifi c mortality at 
the same time minimal improvement, if any, has occurred 
for age-specifi c YLDs per capita. The proportion of 
lifespans spent in ill health has remained comparatively 
constant since 1990, and did not vary as a function of SDI; 
thus, we found nominal evidence of relative compression 
at the global level.
Drawing from our empirical characterisation of 
epidemiological transitions on the basis of SDI, we found 
that life expectancy and HALE increased linearly with 
SDI, whereas years of functional health lost climbed with 
rising SDI. Historically, increases in SDI are associated 
with a rapid decrease in burden from communicable, 
neonatal, maternal, and nutritional diseases, the leading 
killers of children, adolescent girls, and women. Eff orts 
to increase income, provide more years of education, and 
reduce adolescent and total fertility rates thus might 
catalyse additional gains for life expectancy, HALE, and 
reduced disease burden, emphasising the critical role of 
policy interventions beyond more traditional health 
service delivery.
At diff erent locations in this continuous process of 
change, we see evidence of a so-called double burden of 
disease: from a SDI of approximately 0·35 to 0·60, we 
expect NCDs and Group 1 causes to each account for at 
least 20% of disease burden. The average relationships 
with SDI imply that within a country with wide inequalities 
in SDI, we should also expect wide variation in disease 
burden patterns. Subnational disparities might be 
consistent with variations in subnational SDI, either 
recording higher or lower burden than that of the national 
level. Use of average patterns can help to benchmark a 
country against others, but such assessments can also help 
to provide insights as to whether public action or other 
factors are helping make inequalities narrower than 
expected based on SDI alone. Given the complexity of 
health patterns identifi ed for many causes and diff erential 
patterns by age and sex, providing some understanding of 
expected patterns on the basis of SDI alone can help to 
anchor the exploration of results and could provide some 
measure of the performance of health systems or the 
magnitude of avertable burden within each country or 
territory.
The Lancet Commission on Investing in Health40 
galvanised considerable interest in the notion of a “grand 
convergence”, such that levels of under-5 mortality, 
maternal mortality, and some infectious diseases could 
converge across all countries within a generation. 
Convergence can be achieved through progress on in-
creasing SDI (ie, increasing per-capita income and 
average years of schooling, and reducing fertility) 
and reducing or inverting high ratios between observed 
and expected (based on SDI alone) health expectancies and 
health gaps. The Commission has argued that, within a 
generation, preventable deaths in children and mothers 
could largely be avoided through increased investment 
of development assistance for health and expanded 
national expenditure on health. The vision inspired 
some of the absolute threshold SDG targets, including 
reducing under-5 mortality to 25 deaths per 
1000 livebirths, neonatal mortality to 12 deaths per 
1000 livebirths, and maternal mortality ratio to 70 deaths 
per 100 000 livebirths. The relationships between these 
health outcomes, broader health measures, and SDI 
off er a framework by which the likelihood of such a 
grand convergence can be assessed. Based on GBD 2015 
results, the historical relationship between SDI and 
health suggests that convergence in the sense of reduced 
absolute diff erences in rates is likely to occur with faster 
improvements in SDI. However, if convergence means 
smaller relative diff erences, then improvements in SDI 
alone might not be suffi  cient. Our fi ndings show that 
continued SDI improvement does not appear to be 
historically associated with absolute convergence in life 
expectancy or HALE. The Lancet Commission also 
emphasised the importance of hastening progress 
through strategic investments by donors and govern-
ments in eff ective health technologies, an approach that 
has the potential to catalyse faster progress than what 
would be expected on the basis of SDI alone. 
Convergence in this scenario could then be interpreted 
as reduction in the ratio of observed to expected burden 
for low-income and lower-middle-income countries 
(LMICs), and could be used as an indirect, but summary, 
metric to monitor health system performance and 
overall progress toward the SDGs. Since history provides 
a perspective for identifying which countries have been 
able to reduce their ratio of observed to expected health 
outcomes, the comprehensive and longitudinal approach 
of the GBD is optimally suited for monitoring health 
system-driven convergence at a macro-level. The same 
tools can also therefore be used to generate insights on 
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progress, or lack thereof, on specifi c diseases and 
outcomes of interest. In some cases, there might be 
historical or geographical explanations for high burden 
for some conditions. In other cases, eff ective preventive 
and treatment measures have just not yet been 
implemented or are not functioning eff ectively.
Shifting from the MDGs to the SDGs dramatically 
broadened the global health agenda.2,3 The SDGs include 
17 goals, 169 targets, and 230 indicators; of these 
measures, 11 goals, 28 targets, and 46 indicators are 
health related.41 At present, 33 of the 46 health-related 
indicators are measured by the GBD study. Amid earlier 
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discussions and negotiations over SDG 3 indicators, 
HALE was proposed as an indicator of overarching 
health status and progress;2 this proposal was not 
ultimately adopted in the fi nal set of indicators. HALE 
provides a strong summary measure of overall health 
status because it accounts for functional health loss in 
addition to age-specifi c mortality. Other summary 
development measures, such as the Human 
Development Index, have considered replacing life 
expectancy with HALE as an input to the overall 
assessment.42 The GBD study measures health outcomes 
that are both amenable to intervention and could be risk 
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standardised, thus off ering a useful set of metrics to 
monitor progress toward specifi c SDG targets, such as 
the aim of target 3.8 to achieving eff ective universal 
health coverage.
DALYs and other health-gap metrics are one of many 
potential inputs when setting health policy and investment 
priorities, but major research organisations and funders 
such as the US National Institutes of Health and others 
note the use of DALYs to inform budgeting decisions.43–46 
Beyond health metrics, many other inputs are required for 
decision making, ranging from the eff ectiveness of 
diff erent adoptable policies and programmes, to key 
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social, cultural, and ethical considerations. Nonetheless, 
DALYs and other summary health measures might have 
an even more prominent role in the future in setting 
research and development priorities within the health 
sector, particularly in the absence of robust information 
on the eff ectiveness or likely success of various research 
projects and programmes.47 As global health research 
funders increasingly use DALYs to shape priority-setting 
processes, health challenges faced by populations with 
less health-care market power, namely poor people, will 
inevitably receive more attention. Shifting to the use of 
disease burden for programme design and evaluation 
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would benefi t poor people, but also potentially increase 
overall effi  ciency of health research.48 For instance, 
individuals who have historically underfunded conditions, 
such as mental health disorders, substance use, and 
musculoskeletal conditions, would benefi t from the 
greater use of DALYs in decision-making processes.
Global progress has been especially rapid in reducing 
disease burden due to a number of communicable 
diseases, including diarrhoeal diseases, lower respiratory 
infections, tuberculosis, syphilis, typhoid, paratyphoid, 
and vaccine-preventable infections such as hepatitis B, 
measles, tetanus, and Haemophilus infl uenzae type b. To 
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these successes, the last decade has seen profound 
declines in the burden from malaria and HIV/AIDS. NCD 
trends have been much more complicated. For the leading 
cause of disability, low back and neck pain, a lack of 
knowledge about risks limits the opportunity for 
prevention. Occupational ergonomic factors and high 
body-mass index (BMI) are estimated to be responsible for 
30·9% (29·2–32·5) and 5·5% (3·4–7·6) of YLDs due to 
low back pain, respectively.49 The highest occupational risk 
is found in service industries and manual labour, 
especially agriculture.50,51 The relatively small proportion of 
low back pain that is caused by high BMI is amenable to 
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intervention, but the continued escalation of obesity rates 
indicates that these measures might have little 
eff ectiveness. With increasing SDI, the proportion of the 
workforce in agriculture would be expected to become 
smaller, which would have some eff ect on the burden of 
low back pain. Yet, based on our analyses, nearly 65% of 
the burden would remain. The management of most low 
back and neck pain is largely focused on pain relief and 
prevention of worsening outcomes through physical 
therapy and exercise; given the very large burden and the 
associated economic consequences of lost work time, low 
back and neck pain should be a priority for research to 
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identify more eff ective preventive and therapy measures.52 
Similarly, despite broad decreases in age-standardised 
rates of injury burden, the pace of progress for these 
causes has been comparatively slow and ultimately has led 
to minimal changes in the proportion of overall burden 
due to injuries during the past 25 years. Prevention of 
injuries requires strong public safety policies,53 but 
minimising mortality and long-term disability from 
injuries hinges upon having comprehensive trauma care 
systems54,55 that provide timely, evidence-based care,56–58 
including emergency surgical services.59,60
In 2015, sense organ disorders were the second-leading 
cause of YLDs and resulted in more than 68 million 
DALYs. Reducing DALYs from vision impairment is 
achievable through vertically integrated programmes, 
including the delivery of eyeglasses for refractive error, 
curative surgery for cataracts, and onchocerciasis and 
trachoma prevention. Given the availability of cost-
eff ective interventions, greater policy attention is needed 
for vision loss burden. Although interventions for hearing 
loss are less clear, the use of timely antibiotics for otitis 
media and meningitis and the provision of hearing aids 
for conductive hearing loss are likely to reduce its burden.
Reductions in age-standardised DALY rates due to some 
NCDs such as cardiovascular diseases, most cancers, 
chronic respiratory diseases, and many digestive 
diseases—some of which can be attributed to reductions 
in risk factors such as tobacco and improvements in cause-
specifi c treatment and event survival—mask the eff ects of 
population ageing. This means more people had disease 
burden from these causes and total DALYs have remained 
largely unchanged (eg, chronic obstructive pulmonary 
disease) or signifi cantly increased (eg, cardiovascular 
diseases, cancers, neurological disorders, diabetes, chronic 
kidney disease, and musculoskeletal disorders such as 
osteoarthritis and low back and neck pain) over time. As 
demographic transitions are widely expected to continue, 
the burden from NCDs is likely to continue expanding. 
Widespread eff orts must continue to enact societal and 
environmental policies to reduce risk factor exposure, 
while national and local health systems must adapt to meet 
the prevention, screening, and treatment needs of their 
populations. As we now recognise many of the risk factors 
related to NCDs, low-SDI and middle-SDI countries could 
adopt policies to circumvent the mistakes made by other 
countries as they progressed along the SDI spectrum. 
Mental and substance use disorders are a particularly 
challenging group of conditions with non-trivial levels of 
disease burden in all geographies. Some countries provide 
excellent mental health resources, whereas others, 
particularly LMICs, do not have screening or treatment 
programmes. Addressing the growing burden and 
disparity in mental health disorders will be an especially 
pressing challenge during the SDG era.
A number of emerging and growing health threats also 
deserve special attention in policy planning, including 
infectious diseases such as outbreaks of dengue fever, 
Ebola virus disease, Zika virus, and pandemic infl uenza, 
and antimicrobial-resistant pathogens, which represent 
acute threats to life and highlight health-system defi ciencies 
where they occur; substance abuse disorders, particularly of 
opioids and cocaine, in eastern Europe, Australia, and 
North America; and intentional fi rearm injuries, especially 
in Latin America, the USA, and South Africa. In the case of 
dengue fever and potentially other yet to be identifi ed 
infectious diseases, urbanisation and global environmental 
change have contributed to an increased incidence and 
future climate change scenarios depict a rising trend in the 
coming years.61 Other emerging infectious diseases, 
including Zika and chikungunya viruses, have yet to be 
comprehensively analysed by the GBD.
A major change in the GBD 2015 assessment has been 
the closer integration of the assessments of mortality and 
disease sequelae prevalence in modelling. For cancers, 
HIV/AIDS, and injuries, previous iterations of the GBD 
modelled mortality, incidence, and prevalence in a 
coherent manner. For some other diseases, the modelling 
of disease prevalence and cause-specifi c mortality rates 
largely used diff erent data sources and modelling 
techniques. Independent estimation of prevalence and 
mortality led in some cases to patterns across locations of 
excess mortality rates that were not consistent with 
expected relationships related to health-system access. 
For GBD 2015, we built the modelling of cause-specifi c 
mortality, excess mortality, incidence, and prevalence 
into nearly every cause. The eff ect of this approach has 
led to increases in the number of DALYs from injuries 
due to YLDs and changes in prevalence for other 
conditions, particularly those with minimal data for 
prevalence or incidence. More attention will be paid in 
future iterations of the GBD study to identifying 
unpublished data from cohort studies or linkage studies 
Figure 7: Leading ten causes of DALYs with the ratio of observed DALYs to DALYs expected on the basis of SDI in 2015, by location
The ratio of observed DALYs to DALYs expected based on SDI is provided in brackets for each cause and cells are colour coded by ratio ranges (calculated to place a roughly equal number of cells into each bin). 
Shades of blue represent much lower observed DALYs than expected levels based on SDI, whereas red shows observed DALYs that exceed expected levels. IHD=ischaemic heart disease. Back & neck=low back 
and neck pain. Diabetes=diabetes mellitus. Stroke=Cerebrovascular disease. Lung C=lung, bronchus, and trachea cancers. Sense=sense organ diseases. Depression=depressive disorders. Alzheimer’s=Alzheimer’s 
disease and other dementias. Oth MSK=other musculoskeletal disorders. COPD=chronic obstructive pulmonary disease. NN Preterm=neonatal preterm birth complications. Diarrhoea=diarrhoeal diseases. 
Skin=skin and subcutaneous diseases. NN Enceph=neonatal encephalopathy due to birth asphyxia and trauma. Drugs=drug use disorders. Congenital=congenital anomalies. Liver C=liver cancer. 
Stomach C=stomach cancer. CKD=chronic kidney disease. Anxiety=anxiety disorders. Iron=iron-defi ciency anaemia. HIV=HIV/AIDS. Colorect C=colon and rectum cancer. LRI=lower respiratory infections. 
Cirr HepC=cirrhosis due to hepatitis C. CMP=cardiomyopathy and myocarditis. Cirr alc=cirrhosis due to alcohol use. Other Cardio=other cardiovascular and circulatory diseases. Alcohol=alcohol use disorders. 
Violence=interpersonal violence. HTN HD=hypertensive heart disease. Haemog=haemoglobinopathies and haemolytic anaemias. TB=tuberculosis. Prostate C=prostate cancer. War=collective violence and legal 
intervention. Other Unint= other unintentional injuries. Oth trans=other transport injuries. Other NN=Other neonatal disorders. NN Sepsis=neonatal sepsis and other neonatal infections. PEM=protein-energy 
malnutrition. STD=sexually transmitted diseases excluding HIV. Ebola=Ebola virus disease. Other NTD=other neglected tropical diseases. GBD=Global Burden of Disease. SDI=Socio-demographic Index. 
DALYs=disability-adjusted life-years.
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on levels of excess mortality by age and sex, especially in 
LMICs, to further strengthen modelling eff orts.
A major development for the GBD 2015 has been 
adaptation of the GATHER guidelines endorsed by WHO, 
the Institute for Health Metrics and Evaluation (IHME), 
and other organisations.22,23 GATHER compliance, 
including the sharing of statistical code for each of the 
many analytical steps in the GBD, provides a new level of 
transparency for the overall enterprise. We expect that 
many researchers will want to investigate, propose 
improvements, and provide alternative assessments for 
many components of the GBD. We welcome the debate 
that will follow on the best way to analyse diff erent 
components of the GBD. We believe enhanced 
transparency will lead to healthy debate and exchange 
and to improved methods, data, and results for many 
aspects of the GBD. Transparency will not necessarily 
lead to consensus but it will broaden everyone’s 
understanding of the available evidence on descriptive 
epidemiology. Adoption by the GBD of the GATHER 
guidelines will hopefully stimulate other organisations to 
adopt the guidelines in all aspects of their work as well.
Although the volume of input data to the GBD has 
continued to increase substantially, major data gaps 
remain.12,20,62,63 Geographical and temporal coverage of all-
cause and cause-specifi c mortality datasets are variable, as 
is the quality of the data contained in such systems. 
Development of methods to report overall evidence grades 
for each outcome–location–year combination would be 
valuable to help to guide strategies for improving data 
quality and closing data gaps. Investing to develop and 
improve cause of death and vital registration systems is 
crucial to improve the quality of insights from the GBD; 
incorporation of existing data from existing and new 
collaborators that are not currently in the GBD is another 
important aspect of this eff ort. Several countries have 
experienced signifi cant recent turmoil, especially armed 
confl ict in Syria, Yemen, and other countries in north 
Africa and the Middle East. Burden from many conditions 
is believed to have increased during and following those 
events, but due to disruption of data-collection systems, the 
full eff ect of such events has been diffi  cult to quantify. For 
non-fatal health outcomes, some of the most notable data 
gaps pertain to aspects of individual diseases and injuries 
that are not typically included as part of standard 
epidemiological reports such as distribution of symptoms 
for those with chronic conditions at various stages of 
illness, duration of disability following acute events, or 
long-term disability after major acute injuries. Therefore, 
our recommendations regarding data gaps pertaining to 
non-fatal health loss are twofold. First, reports and scientifi c 
journals should strive to include reporting on functional 
health status including severity, distribution, and duration 
of symptoms with all epidemiological studies. Second, 
countries should work to centralise and compile existing 
non-fatal health data and invest to collect population-level 
epidemiological data on important causes of YLDs.
The iterative and now annual cycle of the GBD revisions 
provide opportunities to improve the estimation or scope 
of the GBD. Due to the high interest in Zika virus, we 
believe that we should try to quantify the burden related 
to Zika virus disease in the GBD 2016 analysis. Given the 
focus in the SDGs on various forms of sexual violence, we 
believe careful investigation of the evidence base for 
estimation is warranted. As noted in the GBD papers on 
mortality and non-fatal outcomes,12,20 there are also a 
number of opportunities to improve data processing and 
estimation methods that will be explored for the next 
cycle of estimation. We also expect to include more 
subnational analyses, particularly for large countries.
Our analysis has several limitations. First and foremost, 
the calculation of DALYs and HALE refl ects the limitations 
of all the underlying analyses of the GBD, including all-
cause mortality, cause-specifi c mortality, prevalence, 
incidence, disability-weight derivation, and simulation of 
comorbidity. Second, as discussed above, data limitations 
are apparent in a number of facets of our analysis. Third, 
inherent to the GBD approach is the eff ort to quantify 
specifi c sequelae of each disease and injury. This means 
that the full disease burden of certain conditions such as 
heart failure, anaemia, vision and hearing loss, infertility, 
epilepsy, and intellectual disability are not as readily 
apparent in high-level review of the GBD results. However, 
the YLDs for these impairments are reported elsewhere.20 
Fourth, our analysis of the relationship between SDI, 
DALYs, and HALE refl ects the average historical 
relationship between SDI and each measure, so despite 
often strong correlation with SDI it cannot be interpreted 
as being causal in nature. In some cases, association of SDI 
with health indicators could be considered a confounder 
when the same elements (education, income, and fertility) 
are used to develop both the index and as a covariate in 
cause-specifi c models. SDI utility might be improved in the 
future through consideration of additional societal 
elements such as inequality in each component. Other 
measures that capture the status of women in society, such 
as the female labour-force participation, could be considered 
in future revisions. Fifth, we have assumed independence 
of uncertainty between YLLs and YLDs as well as between 
YLDs and life expectancy. Empirical evidence to guide 
alternative assumptions, however, is currently very limited. 
Sixth, recent events in Syria and Libya and the resulting 
mass migration have led to considerable health loss, 
including drownings of many migrants. New migrants 
have diff erent health problems than the populations of the 
countries to which they have moved. Both the drownings 
and the change in health status in countries receiving 
migrants are not adequately captured in this assessment 
due to the time-lags in data collection and data capture 
intrinsic in all health data systems. Seventh, estimates of 
expected burden from SDI alone are based on the average 
levels of burden at each level of SDI. For endemic diseases, 
comparisons of observed rates to expected rates will lead to 
high observed over expected ratios in endemic countries 
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and low ratios in non-endemic countries. Interpretation of 
the ratios for conditions that are endemic in only some 
countries needs to take this into account.
WHO has estimated DALYs by cause for the single years 
of 2000 and 2012.13,17 They used published GBD 2010 results 
used to generate WHO 2012 DALYs for 132 causes with 
some modifi cations. First, WHO life tables were used 
instead of GBD life tables.14 WHO life tables are diff erent 
from the UN Population Division life tables and use a set of 
methods developed by Murray and colleagues in the late 
1990s;11,64 this approach does not benefi t from the many 
improvements in data processing and estimation methods 
that have emerged in the last 15 years.12,65,66 Second, WHO 
altered the empirical disability weights, which were derived 
from an international sample of more than 
60 000 respondents from the GBD analysis26 for 32 out -
comes using the opinions of 45 respondents.13,67 Third, 
WHO calculated YLLs after changing from the GBD 2010 
normative standard life expectancy of 86·0 years to 
91·9 years.68 Fourth, rather than using GBD results, WHO 
elected to use alternative estimates for 12 causes of death, 
including tuberculosis, HIV/AIDS and other sexually 
transmitted infections, malaria, whooping cough, measles, 
schistosomiasis, maternal disorders, cancers, alcohol and 
drug use disorders, epilepsy, confl ict and natural disasters, 
and road traffi  c accidents.13 Finally, WHO substituted 
prevalence estimates produced internally for vision loss, 
hearing loss, intellectual disability, infertility, anaemia, back 
pain, alcohol use disorders, headache, and skin diseases. 
The fi nal hybrid estimates of DALYs do not provide 
uncertainty measures and have not been peer-reviewed. 
WHO has also produced HALE estimates for three 
time periods, 2000, 2012, and 2015, using GBD 2010 
results as described above for 2000 and 2012, and GBD 
2013 results for 2015, also without uncertainty measures.14 
Diff erences between their estimates and those for HALE 
from GBD 2015 refl ect changes in age-specifi c YLDs per 
capita from GBD 2013 to GBD 2015 and diff erences in 
WHO life expectancy (appendix p 85). The EC and the 
OECD also report healthy life expectancy estimates based 
on self-reported health status from 2004 through 2014, 
but without specifi c consideration of prevalence or 
incidence of disease.52,53 Comparison of 2014 estimates 
from the EC and GBD mostly show lower estimates from 
EC (appendix pp 86–87). EC estimates also report much 
wider ranges in HALE across countries in Europe than 
those estimated through GBD. Further, in a number of 
countries, EC estimates point to lower HALE among 
women than for men. These diff erences, both in terms of 
absolute estimates and those by sex, are probably due to 
the inclusion of non-health factors in self-reported 
assessments of disability.
In conclusion, HALE has increased steadily throughout 
the world over the MDG era, with a concomitant decrease 
in age-standardised DALY rates from most conditions. 
Declines occurred in overall health loss due to many 
communicable, maternal, neonatal, and nutritional 
diseases. Much of the evolution of health is consistent with 
the expected changes in disease burden with development 
that have been quantifi ed in this study. Substantial 
variation in burden compared with levels expected on the 
basis of SDI suggests wide heterogeneity in the ability of 
governments and health systems to adequately meet the 
health needs of their populations. Progress in reducing 
these gaps will be crucial to achieving the ambitious SDG 
agenda. Demographic changes leading to increased 
population size and older average age have off set otherwise 
important gains in age-specifi c DALY rates leading to 
rising burden on health systems for many ailments of 
ageing. Emerging health threats and causes with lagging 
progress should be viewed as essential foci for investment 
in health infrastructure and health data systems to improve 
the global community’s insights into the aggregate quality 
of care and the overall health of populations.
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